衛材在華企業隸屬于衛材株(zhu)式會社,衛材株(zhu)式會社是一家以(yi)研(yan)究開發(fa)醫藥產品(pin)為主(zhu)的跨國公司,總部設(she)在日(ri)本東京。
衛(wei)(wei)(wei)材(cai)(cai)(cai)中(zhong)國(guo)自(zi)上世紀90年(nian)(nian)代初進入中(zhong)國(guo)市場(chang)以來(lai)順利發展壯大(da)。自(zi)1991年(nian)(nian)先后(hou)成立沈陽衛(wei)(wei)(wei)材(cai)(cai)(cai)制藥(yao)有(you)(you)限(xian)(xian)公(gong)(gong)司(si)(si)和衛(wei)(wei)(wei)材(cai)(cai)(cai)(蘇(su)州(zhou))制藥(yao)有(you)(you)限(xian)(xian)公(gong)(gong)司(si)(si),并(bing)于2002年(nian)(nian)正式更(geng)名為衛(wei)(wei)(wei)材(cai)(cai)(cai)(中(zhong)國(guo))藥(yao)業(ye)有(you)(you)限(xian)(xian)公(gong)(gong)司(si)(si)。伴隨著中(zhong)國(guo)業(ye)務的發展,于2010年(nian)(nian)成立衛(wei)(wei)(wei)材(cai)(cai)(cai)(蘇(su)州(zhou))貿易(yi)有(you)(you)限(xian)(xian)公(gong)(gong)司(si)(si),于2014年(nian)(nian)成立衛(wei)(wei)(wei)材(cai)(cai)(cai)(中(zhong)國(guo))投資有(you)(you)限(xian)(xian)公(gong)(gong)司(si)(si),并(bing)于2015年(nian)(nian)通過(guo)全額收購本地仿制藥(yao)企(qi)業(ye)正式成立衛(wei)(wei)(wei)材(cai)(cai)(cai)(遼(liao)寧(ning))制藥(yao)有(you)(you)限(xian)(xian)公(gong)(gong)司(si)(si)。至此,形成了以衛(wei)(wei)(wei)材(cai)(cai)(cai)(中(zhong)國(guo))投資有(you)(you)限(xian)(xian)公(gong)(gong)司(si)(si)為資控管(guan)理,以衛(wei)(wei)(wei)材(cai)(cai)(cai)(中(zhong)國(guo))藥(yao)業(ye)有(you)(you)限(xian)(xian)公(gong)(gong)司(si)(si)、衛(wei)(wei)(wei)材(cai)(cai)(cai)(遼(liao)寧(ning))制藥(yao)有(you)(you)限(xian)(xian)公(gong)(gong)司(si)(si)、衛(wei)(wei)(wei)材(cai)(cai)(cai)(蘇(su)州(zhou))貿易(yi)有(you)(you)限(xian)(xian)公(gong)(gong)司(si)(si)為業(ye)務支(zhi)撐的發展模式。為適(shi)應中(zhong)國(guo)業(ye)務的迅速發展,2014年(nian)(nian)11月衛(wei)(wei)(wei)材(cai)(cai)(cai)(中(zhong)國(guo))藥(yao)業(ye)有(you)(you)限(xian)(xian)公(gong)(gong)司(si)(si)注射(she)劑(ji)工廠(chang)竣工, 2017年(nian)(nian)11月新固體制劑(ji)廠(chang)房(fang)落成,衛(wei)(wei)(wei)材(cai)(cai)(cai)中(zhong)國(guo)的產能(neng)得到(dao)迅速提升。
目前,總注(zhu)冊資本10,854萬美(mei)金。已形成以(yi)神經科學(xue)領(ling)域(yu)、腫瘤(特藥)領(ling)域(yu)、消(xiao)化(hua)肝病領(ling)域(yu)為主要(yao)領(ling)域(yu),拓展仿制藥領(ling)域(yu),多達數(shu)十種藥品在中國(guo)銷售的發展規(gui)模。
未來,蘇州工廠除滿(man)足中國患者臨床用藥(yao)的需求外,將向亞(ya)洲其它國家和地區同(tong)樣提供高品(pin)質滿(man)足患者需求的產(chan)品(pin)。